Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
pelareorep
product9 mentionslast seen Nov 12, 2026
Intravenously delivered, systemically active, investigational immunotherapy with dual mechanism of action.
Relationships 26
- Oncolytics Biotech Inc.developspelareorep99% confidence9 sources
- U.S. Food and Drug Administrationapprovespelareorep99% confidence4 sources
- pelareorepapplies topancreatic cancer treatment99% confidence4 sources
- pelareorepapplies toanal cancer treatment99% confidence3 sources
- pelareorepapplies togastrointestinal cancer treatment99% confidence3 sources
- pelareorepapplies tometastatic breast cancer treatment99% confidence3 sources
- pelareorepapplies tocolorectal cancer treatment99% confidence2 sources
- pelareorepapplies topancreatic cancer99% confidence2 sources
- pelareorepapplies tometastatic colorectal cancer treatment99% confidence2 sources
- pelareorepapplies tocolorectal cancer99% confidence2 sources
- pelareorepapplies toHPV-driven cancers98% confidence2 sources
- pelareorepapplies tocancer immunotherapy95% confidence1 source
- pelareorepapplies torelapsed/refractory multiple myeloma treatment95% confidence1 source
- pelareorepapplies tohepatocellular carcinoma treatment95% confidence1 source
- pelareorepapplies tosquamous cell anal cancer treatment95% confidence1 source
- pelareorepapplies tosquamous cell anal carcinoma treatment94% confidence1 source
- pelareorepapplies toanal cancer93% confidence1 source
- pelareorepdepends onatezolizumab93% confidence1 source
- pelareorepapplies tosquamous cell anal cancer92% confidence1 source
- pelareorepapplies tometastatic breast cancer85% confidence1 source
- pelareorepcomposed ofdouble-stranded RNA85% confidence1 source
- pelareorepapplies tometastatic gastrointestinal cancers85% confidence1 source
- MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinomacitespelareorep85% confidence1 source
- pelareorepdepends oncheckpoint inhibitor82% confidence1 source
- pelareorepapplies toHPV-associated head and neck squamous cell carcinoma75% confidence1 source
- pelareorepapplies toHPV-associated cancer treatment75% confidence1 source
Relationship
pelareorepapplies tometastatic colorectal cancer treatment
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 20, 2026ONCOLYTICS BIOTECH INC 8-K: Item 8.01: Other Events
for the second-line treatment of RAS-mutated, microsatellite-stable (MSS) metastatic colorectal cancer
- filingSEC EDGARSep 28, 2026ONCOLYTICS BIOTECH INC 8-K: Item 8.01: Other Events
pelareorep in second-line RAS-mutant, microsatellite-stable (MSS) metastatic colorectal cancer (mCRC)